First-line panitumumab plus docetaxel and cisplatin in advanced gastric and gastro-oesophageal junction adenocarcinoma: results of a phase II trial

  • G. Quintero AldanaEmail author
  • M. Salgado
  • S. Candamio
  • J. C. Méndez
  • M. Jorge
  • M. Reboredo
  • L. Vázquez Tuñas
  • C. Romero
  • M. Covela
  • A. Fernández Montes
  • M. Carmona
  • Y. Vidal Insua
  • R. López
  • the Galician Oncological Research Group (GGIO)
Research Article



Panitumumab is extensively used for RAS-WT metastatic colorectal cancer. This study assessed the efficacy and safety of panitumumab plus first-line chemotherapy [docetaxel (DOC) and cisplatin (CIS)] in treatment-naïve advanced gastric or gastro-oesophageal junction (GEJ) adenocarcinoma (ADC) patients.


Phase II, open-label, single-arm study includes treatment-naïve advanced gastric or GEJ-ADC patients from ten Spanish centres. Patients received panitumumab (6 mg/kg) plus DOC and CIS (50 mg/m2 both) every 2 weeks until disease progression, unacceptable toxicity, or patient withdrawal. Primary endpoint: objective response rate (ORR); main secondary endpoints: disease control rate (DCR), duration of response (DoR), time to progressive disease (TTP), progression-free-survival (PFS), overall survival (OS), and safety.


Forty-four patients were included; median age: 67.8 (range 43.3–82.7) years, 68.2% male. The ORR was 27.3% (95% CI 15.0, 42.8); median PFS and OS: 5.0 (95% CI 3.6, 6.9) and 7.2 (5.5, 9.0) months, respectively. Median TTP, DCR and DoR: 5.3 (range 3.8–7.0) months, 70.5% (95% CI 54.8, 83.2%), and 4.8 (1.8, NE) months. Median panitumumab treatment duration: 11.9 (range 0.1–34.9) weeks; 25.0% patients had a dose reduction and 40.9% discontinued treatment. Grade 3–4 adverse events (AEs): 68.2%/22.2% patients. Most common AEs: asthenia (75.0%) and mucosal inflammation (54.5%). Serious AEs were experienced by 54.6% patients; 9.1%, 13.6%, and 15.9% related to panitumumab, DOC, and CIS, respectively. Three (6.8%) patients died due to AEs not related to study treatment.


The addition of panitumumab to standard chemotherapy as the first-line treatment in advanced gastric or GEJ-ADC does not appear to improve the efficacy outcomes.


Panitumumab Docetaxel Cisplatin Gastric cancer Gastro-oesophageal junction 



Writing assistance was supported by Amgen and provided by Cristina Ceballos, MSc, Nerea Gallastegui, PhD, and Neus Valveny, PhD, from TFS Develop. The authors wish to thank to all the investigators of the SPIGA Study.


This work was supported by Amgen S.A. Amgen did not have any role in study design; collection, analysis, and interpretation of data; writing the report; and the decision to submit the report for publication.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This study was approved by the Ethic Committee of Reference (Comité Ético de Investigación Clínica SERGAS, Santiago de Compostela, Spain) and the Spanish Health Authorities (AEMPS), and conducted in accordance with the principles of the Declaration of Helsinki.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Stewart BW, Wild CP, editors. World Cancer Report 2014. Lyon, France: International Agency for Research on Cancer. 2014.Google Scholar
  2. 2.
    Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 2012. Accessed September 23, 2015.
  3. 3.
    Al-Batran S-E, Lorenzen S. Management of Locally Advanced Gastro-oesophageal Cancer: Still a Multidisciplinary Global Challenge? Hematol Oncol Clin North Am. 2017;31:441–52. Scholar
  4. 4.
    Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991–7. Scholar
  5. 5.
    Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastro-oesophageal adenocarcinoma. J Clin Oncol. 2005;23:5660–7. Scholar
  6. 6.
    Kim JY, Do YR, Park KU, Kim MK, Lee KH, Bae SH, et al. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. Cancer Chemother Pharmacol. 2010;66:31–6. Scholar
  7. 7.
    Quintero-Aldana G, Jorge M, Grande C, Salgado M, Gallardo E, Varela S, et al. Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer. Cancer Chemother Pharmacol. 2015;76:731–7. Scholar
  8. 8.
    Woo J, Cohen SA, Grim JE. Targeted therapy in gastro-oesophageal cancers: past, present and future. Gastroenterol Rep. 2015;3:316–29. Scholar
  9. 9.
    Cervantes A, Rodríguez Braun E, Pérez Fidalgo A, Chirivella González I. Molecular biology of gastric cancer. Clin Transl Oncol. 2007;9:208–15.CrossRefGoogle Scholar
  10. 10.
    Lordick F, Kang Y-K, Chung H-C, Salman P, Oh SC, Bodoky G, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): A randomised, open-label phase 3 trial. Lancet Oncol. 2013;14:490–9. Scholar
  11. 11.
    Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AFC, Frances A, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14:481–9. Scholar
  12. 12.
    Tebbutt NC, Price TJ, Ferraro DA, Wong N, Veillard A-S, Hall M, et al. Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial. Br J Cancer. 2016;114:505–9. Scholar
  13. 13.
    Pinto C, Di Fabio F, Barone C, Siena S, Falcone A, Cascinu S, et al. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer. 2009;101:1261–8. Scholar
  14. 14.
    Chan JA, Blaszkowsky LS, Enzinger PC, Ryan DP, Abrams TA, Zhu AX, et al. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol. 2011;22:1367–73. Scholar
  15. 15.
    Gold PJ, Goldman B, Iqbal S, Leichman LP, Zhang W, Lenz H-J, et al. Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415). J Thorac Oncol. 2010;5:1472–6. Scholar
  16. 16.
    Park KW, Ahn JS, Park YS, Lee J, Kang JH, Park JO, et al. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer. Cancer Chemother Pharmacol. 2007;59:17–211. Scholar
  17. 17.
    Aoyagi K, Kouhuji K, Kizaki J, Isobe T, Hashimoto K, Shirouzu K. Molecular targeting to treat gastric cancer. World J Gastroenterol. 2014;20:13741–55. Scholar
  18. 18.
    Abraham I, Alhossan A, Lee CS, Kutbi H, MacDonald K. “Real-life” effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy. 2015. Google Scholar
  19. 19.
    Pasini F, Fraccon AP, Modena Y, Bencivenga M, Giacopuzzi S, La Russa F, et al. Targeted therapies for advanced and metastatic adenocarcinoma of the gastro-oesophageal junction: is there something new? Gastric Cancer. 2017;20:31–42. Scholar
  20. 20.
    Raufi AG, Klempner SJ. Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. J Gastrointest Oncol. 2015;6:561–9. Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2019

Authors and Affiliations

  • G. Quintero Aldana
    • 1
    Email author
  • M. Salgado
    • 2
  • S. Candamio
    • 3
  • J. C. Méndez
    • 4
  • M. Jorge
    • 5
  • M. Reboredo
    • 6
  • L. Vázquez Tuñas
    • 7
  • C. Romero
    • 8
  • M. Covela
    • 1
  • A. Fernández Montes
    • 2
  • M. Carmona
    • 1
  • Y. Vidal Insua
    • 3
  • R. López
    • 3
    • 9
  • the Galician Oncological Research Group (GGIO)
  1. 1.Department of Medical OncologyHospital Universitario Lucus AugustiLugoSpain
  2. 2.Department of Medical OncologyComplejo Hospitalario Universitario de OurenseOurenseSpain
  3. 3.Department of Medical OncologyComplejo Hospitalario Universitario de Santiago de CompostelaSantiago de CompostelaSpain
  4. 4.Department of Medical Oncology, Centro Oncologico de GaliciaA CoruñaSpain
  5. 5.Department of Medical OncologyComplejo Hospitalario Xeral CíesVigoSpain
  6. 6.Department of Medical OncologyComplejo Hospitalario Universitario A CoruñaA CoruñaSpain
  7. 7.Department of Medical OncologyComplejo Hospitalario de PontevedraPontevedraSpain
  8. 8.Department of Medical OncologyHospital POVISAVigoSpain
  9. 9.CIBERONCMadridSpain

Personalised recommendations